Rafferty Asset Management
ABUS icon

Rafferty Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Rafferty Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$553K Buy
122,854
+5,822
+5% +$25.5K ﹤0.01% 874
2025
Q4 		$563K Buy
117,032
+64,024
+121% +$288K ﹤0.01% 888
2025
Q3 		$241K Sell
53,008
-35,446
-40% -$130K ﹤0.01% 1040
2025
Q2 		$273K Buy
88,454
+5,590
+7% +$18.6K ﹤0.01% 999
2025
Q1 		$289K Sell
82,864
-63,939
-44% -$213K ﹤0.01% 971
2024
Q4 		$480K Buy
146,803
+31,782
+28% +$117K ﹤0.01% 920
2024
Q3 		$443K Buy
+115,021
New +$441K ﹤0.01% 966
2023
Q2 		– Sell
-31,693
Closed -$96K – 1091
2023
Q1 		$96K Sell
31,693
-62,812
-66% -$177K ﹤0.01% 1126
2022
Q4 		$220K Buy
94,505
+40,176
+74% +$96.1K ﹤0.01% 1066
2022
Q3 		$104K Sell
54,329
-13,407
-20% -$31.6K ﹤0.01% 1124
2022
Q2 		$184K Buy
67,736
+7,335
+12% +$18.8K ﹤0.01% 1046
2022
Q1 		$180K Buy
60,401
+35,879
+146% +$110K ﹤0.01% 1156
2021
Q4 		$95K Buy
+24,522
New +$95.3K ﹤0.01% 1259

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Rafferty Asset Management's ABUS Position: Q1 2026 in Review

Rafferty Asset Management increased its Arbutus Biopharma (ABUS) stake by 5% in Q1 2026, buying an estimated $25.5K and bringing the position to 122,854 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #874.

Rafferty Asset Management first reported a position in ABUS in Q4 2021 and has held it in 13 quarters since. The position peaked at $563K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Rafferty Asset Management held 122,854 shares of Arbutus Biopharma worth $553K as of Q1 2026.
  • Rafferty Asset Management bought 5,822 Arbutus Biopharma shares in Q1 2026, an estimated $25.5K.
  • Arbutus Biopharma made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #874 holding.
  • Rafferty Asset Management first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 13 quarters since.
  • Rafferty Asset Management's Arbutus Biopharma position peaked at $563K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.